QuadMedicine reports 72% increase in operating loss
QuadMedicine reported a 72% increase in operating loss to 7.65 billion won for 2025. Revenue grew 16.9% to 10.87 billion won, while net loss expanded 65.1% to 8.2 billion won.
Polaris AI Pharma's investment in Quadmedicine pays off
Quadmedicine, backed by Polaris AI Pharma, applies for KOSDAQ listing. The company specializes in microneedle drug delivery technology and has partnerships with global pharma companies.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.